Cargando…
Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
An emerging issue in neuroimaging is to assess the diagnostic reliability of PET and its application in clinical practice. We aimed at assessing the accuracy of brain FDG-PET in discriminating patients with MCI due to Alzheimer's disease and healthy controls. Sixty-two patients with amnestic MC...
Autores principales: | Pagani, M., De Carli, F., Morbelli, S., Öberg, J., Chincarini, A., Frisoni, G.B., Galluzzi, S., Perneczky, R., Drzezga, A., van Berckel, B.N.M., Ossenkoppele, R., Didic, M., Guedj, E., Brugnolo, A., Picco, A., Arnaldi, D., Ferrara, M., Buschiazzo, A., Sambuceti, G., Nobili, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299956/ https://www.ncbi.nlm.nih.gov/pubmed/25610765 http://dx.doi.org/10.1016/j.nicl.2014.11.007 |
Ejemplares similares
-
Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
por: Chincarini, A., et al.
Publicado: (2019) -
Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
por: Bauckneht, Matteo, et al.
Publicado: (2018) -
Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)
por: Brugnolo, Andrea, et al.
Publicado: (2021) -
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023) -
Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2019)